• 1
    Hanahan D,Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 35364.
  • 2
    Folkman J. The role of angiogenesis in tumor growth. Semin Cancer Biol 1992; 3: 6571.
  • 3
    Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 2731.
  • 4
    Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000; 6: 38995.
  • 5
    Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 11826.
  • 6
    Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 2007; 6: 27386.
  • 7
    Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005; 307: 5862.
  • 8
    Rad FH,Le Buanec H,Paturance S,Larcier P,Genne P,Ryffel B,Bensussan A,Bizzini B,Gallo RC,Zagury D,Uzan G. VEGF kinoid vaccine, a therapeutic approach against tumor angiogenesis and metastases. Proc Natl Acad Sci USA 2007; 104: 283742.
  • 9
    Niethammer AG,Xiang R,Becker JC,Wodrich H,Pertl U,Karsten G,Eliceiri BP,Reisfeld RA. A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat Med 2002; 8: 136975.
  • 10
    Wei YQ,Huang MJ,Yang L,Zhao X,Tian L,Lu Y,Shu JM,Lu CJ,Niu T,Kang B,Mao YQ,Liu F, et al. Immunogene therapy of tumors with vaccine based on Xenopus homologous vascular endothelial growth factor as a model antigen. Proc Natl Acad Sci USA 2001; 98: 1154550.
  • 11
    Okaji Y,Tsuno NH,Saito S,Yoneyama S,Tanaka M,Nagawa H,Takahashi K. Vaccines targeting tumour angiogenesis—a novel strategy for cancer immunotherapy. Eur J Surg Oncol 2006; 32: 36370.
  • 12
    Ishizaki H,Tsunoda T,Wada S,Yamauchi M,Shibuya M,Tahara H. Inhibition of tumor growth with antiangiogenic cancer vaccine using epitope peptides derived from human vascular endothelial growth factor receptor 1. Clin Cancer Res 2006; 12: 58419.
  • 13
    Li Y,Wang MN,Li H,King KD,Bassi R,Sun H,Santiago A,Hooper AT,Bohlen P,Hicklin DJ. Active immunization against the vascular endothelial growth factor receptor flk1 inhibits tumor angiogenesis and metastasis. J Exp Med 2002; 195: 157584.
  • 14
    Wada S,Tsunoda T,Baba T,Primus FJ,Kuwano H,Shibuya M,Tahara H. Rationale for antiangiogenic cancer therapy with vaccination using epitope peptides derived from human vascular endothelial growth factor receptor 2. Cancer Res 2005; 65: 493946.
  • 15
    Yoneyama S,Okaji Y,Tsuno NH,Kawai K,Yamashita H,Tsuchiya T,Yamada J,Sunami E,Osada T,Kitayama J,Takahashi K,Nagawa H. A study of dendritic and endothelial cell interactions in colon cancer in a cell line and small mammal model. Eur J Surg Oncol 2007; 33: 11918.
  • 16
    Ko E,Luo W,Peng L,Wang X,Ferrone S. Mouse dendritic-endothelial cell hybrids and 4-1BB costimulation elicit antitumor effects mediated by broad antiangiogenic immunity. Cancer Res 2007; 67: 787584.
  • 17
    Wei YQ,Wang QR,Zhao X,Yang L,Tian L,Lu Y,Kang B,Lu CJ,Huang MJ,Lou YY,Xiao F,He QM, et al. Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine. Nat Med 2000; 6: 11606.
  • 18
    Okaji Y,Tsuno NH,Kitayama J,Saito S,Takahashi T,Kawai K,Yazawa K,Asakage M,Hori N,Watanabe T,Shibata Y,Takahashi K, et al. Vaccination with autologous endothelium inhibits angiogenesis and metastasis of colon cancer through autoimmunity. Cancer Sci 2004; 95: 8590.
  • 19
    Chen XY,Zhang W,Zhang W,Wu S,Bi F,Su YJ,Tan XY,Liu JN,Zhang J. Vaccination with viable human umbilical vein endothelial cells prevents metastatic tumors by attack on tumor vasculature with both cellular and humoral immunity. Clin Cancer Res 2006; 12: 583440.
  • 20
    Madri JA,Williams SK. Capillary endothelial cell cultures: phenotypic modulation by matrix components. J Cell Biol 1983; 97: 15365.
  • 21
    Janzer RC,Raff MC. Astrocytes induce blood-brain barrier properties in endothelial cells. Nature 1987; 325: 2537.
  • 22
    Aird WC,Edelberg JM,Weiler-Guettler H,Simmons WW,Smith TW,Rosenberg RD. Vascular bed-specific expression of an endothelial cell gene is programmed by the tissue microenvironment. J Cell Biol 1997; 138: 111724.
  • 23
    St Croix B,Rago C,Velculescu V,Traverso G,Romans KE,Montgomery E,Lal A,Riggins GJ,Lengauer C,Vogelstein B,Kinzler KW. Genes expressed in human tumor endothelium. Science 2000; 289: 1197202.
  • 24
    Zhou YJ,Wang SQ,Zhang J,Zhang W,Bi F,Guo ZG,Ding BS,Kumar P,Liu JN,Tan XY. A novel method to isolate and map endothelial membrane proteins from pulmonary vasculature. Am J Physiol Cell Physiol 2005; 288: C9506.
  • 25
    Rybak JN,Ettorre A,Kaissling B,Giavazzi R,Neri D,Elia G. In vivo protein biotinylation for identification of organ-specific antigens accessible from the vasculature. Nat Methods 2005; 2: 2918.
  • 26
    Jaffe EA,Nachman RL,Becker CG,Minick CR. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest 1973; 52: 274556.
  • 27
    Oh P,Li Y,Yu J,Durr E,Krasinska KM,Carver LA,Testa JE,Schnitzer JE. Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy. Nature 2004; 429: 62935.
  • 28
    Holmes K,Fowlkes BJ,Schmid I,Giorgi JV. Immunofluorescence staining of single-cell suspensions for detection of surface antigens. In: ColiganJ,KruisbeekA,MarguliesD,ShevachE,StroberW, eds. Current protocols in immunology. New York: Wiley, 2002. 5.3.13.
  • 29
    Dimmeler S,Dernbach E,Zeiher AM. Phosphorylation of the endothelial nitric oxide synthase at ser-1177 is required for VEGF-induced endothelial cell migration. FEBS Lett 2000; 477: 25862.
  • 30
    Lichtenfels R,Biddison WE,Schulz H,Vogt AB,Martin R. CARE-LASS (calcein-release-assay), an improved fluorescence-based test system to measure cytotoxic T lymphocyte activity. J Immunol Methods 1994; 172: 22739.
  • 31
    Plate KH,Breier G,Millauer B,Ullrich A,Risau W. Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis. Cancer Res 1993; 53: 58227.
  • 32
    Alessandri G,Chirivi RG,Fiorentini S,Dossi R,Bonardelli S,Giulini SM,Zanetta G,Landoni F,Graziotti PP,Turano A,Caruso A,Zardi L, et al. Phenotypic and functional characteristics of tumour-derived microvascular endothelial cells. Clin Exp Metastasis 1999; 17: 65562.
  • 33
    Boehm T,Folkman J,Browder T,O'Reilly MS. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997; 390: 4047.
  • 34
    Modzelewski RA,Davies P,Watkins SC,Auerbach R,Chang MJ,Johnson CS. Isolation and identification of fresh tumor-derived endothelial cells from a murine RIF-1 fibrosarcoma. Cancer Res 1994; 54: 3369.
  • 35
    Mauceri HJ,Hanna NN,Beckett MA,Gorski DH,Staba MJ,Stellato KA,Bigelow K,Heimann R,Gately S,Dhanabal M,Soff GA,Sukhatme VP, et al. Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature 1998; 394: 28791.
  • 36
    Hurwitz H,Fehrenbacher L,Novotny W,Cartwright T,Hainsworth J,Heim W,Berlin J,Baron A,Griffing S,Holmgren E,Ferrara N,Fyfe G, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 233542.
  • 37
    Corsini E,Gelati M,Calatozzolo C,Alessandri G,Frigerio S,De Francesco M,Poiesi C,Parati E,Croci D,Boiardi A,Salmaggi A. Immunotherapy with bovine aortic endothelial cells in subcutaneous and intracerebral glioma models in rats: effects on survival time, tumor growth, and tumor neovascularization. Cancer Immunol Immunother 2004; 53: 95562.
  • 38
    Scappaticci FA,Nolan GP. Induction of anti-tumor immunity in mice using a syngeneic endothelial cell vaccine. Anticancer Res 2003; 23: 116572.
  • 39
    Zhong ZH,Kusznieruk KP,Popov IA,Riordan NH,Izadi H,Li YJ,Sher S,Szczurko OM,Agadjanyan MG,Tullis RH,Harandi A,Reznik BN, et al. Induction of antitumor immunity through xenoplacental immunization. J Transl Med 2006; 4: 9.
  • 40
    Durr E,Yu J,Krasinska KM,Carver LA,Yates JR,Testa JE,Oh P,Schnitzer JE. Direct proteomic mapping of the lung microvascular endothelial cell surface in vivo and in cell culture. Nat Biotechnol 2004; 22: 98592.
  • 41
    Jacobson BS,Schnitzer JE,McCaffery M,Palade GE. Isolation and partial characterization of the luminal plasmalemma of microvascular endothelium from rat lungs. Eur J Cell Biol 1992; 58: 296306.
  • 42
    Ding BS,Zhou YJ,Chen XY,Zhang J,Zhang PX,Sun ZY,Tan XY,Liu JN. Lung endothelium targeting for pulmonary embolism thrombolysis. Circulation 2003; 108: 28928.
  • 43
    Ghitescu LD,Crine P,Jacobson BS. Antibodies specific to the plasma membrane of rat lung microvascular endothelium. Exp Cell Res 1997; 232: 4755.
  • 44
    Hlatky L,Hahnfeldt P,Folkman J. Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J Natl Cancer Inst 2002; 94: 88393.
  • 45
    Brown J,Reading SJ,Jones S,Fitchett CJ,Howl J,Martin A,Longland CL,Michelangeli F,Dubrova YE,Brown CA. Critical evaluation of ECV304 as a human endothelial cell model defined by genetic analysis and functional responses: a comparison with the human bladder cancer derived epithelial cell line T24/83. Lab Invest 2000; 80: 3745.
  • 46
    Dirks WG,MacLeod RA,Drexler HG. ECV304 (endothelial) is really T24 (bladder carcinoma): cell line cross-contamination at source. In Vitro Cell Dev Biol Anim 1999; 35: 5589.
  • 47
    Suda K,Rothen-Rutishauser B,Gunthert M,Wunderli-Allenspach H. Phenotypic characterization of human umbilical vein endothelial (ECV304) and urinary carcinoma (T24) cells: endothelial versus epithelial features. In Vitro Cell Dev Biol Anim 2001; 37: 50514.
  • 48
    Hughes SE. Functional characterization of the spontaneously transformed human umbilical vein endothelial cell line ECV304: use in an in vitro model of angiogenesis. Exp Cell Res 1996; 225: 17185.
  • 49
    Feng D,Nagy JA,Brekken RA,Pettersson A,Manseau EJ,Pyne K,Mulligan R,Thorpe PE,Dvorak HF,Dvorak AM. Ultrastructural localization of the vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) receptor-2 (FLK-1. KDR) in normal mouse kidney and in the hyperpermeable vessels induced by. VPF/VEGF-expressing tumors and adenoviral vectors. J Histochem Cytochem 2000; 48: 54556.
  • 50
    Natali PG,Hamby CV,Felding-Habermann B,Liang B,Nicotra MR,Di Filippo F,Giannarelli D,Temponi M,Ferrone S. Clinical significance of alpha(v)beta3 integrin and intercellular adhesion molecule-1 expression in cutaneous malignant melanoma lesions. Cancer Res 1997; 57: 155460.
  • 51
    Ross MA,Sander CM,Kleeb TB,Watkins SC,Stolz DB. Spatiotemporal expression of angiogenesis growth factor receptors during the revascularization of regenerating rat liver. Hepatology 2001; 34: 113548.
  • 52
    Singh B,Fu C,Bhattacharya J. Vascular expression of the alpha(v)beta(3)-integrin in lung and other organs. Am J Physiol Lung Cell Mol Physiol 2000; 278: L21726.
  • 53
    Max R,Gerritsen RR,Nooijen PT,Goodman SL,Sutter A,Keilholz U,Ruiter DJ,De Waal RM. Immunohistochemical analysis of integrin alpha vbeta3 expression on tumor-associated vessels of human carcinomas. Int J Cancer 1997; 71: 3204.